Background
Amgen, Inc. owned a foundational portfolio of patents covering erythropoietin (EPO) — a naturally occurring hormone that controls red blood cell production. Amgen’s scientists had cloned the human EPO gene and developed methods for producing recombinant human EPO in mammalian cell cultures. The resulting biologic drug, marketed as Epogen and Procrit, became one of the most commercially successful drugs in history, used widely to treat anemia in dialysis patients and cancer chemotherapy patients. Amgen’s patents covered the EPO protein itself, recombinant DNA molecules encoding EPO, host cells transformed to produce EPO, and pharmaceutical compositions containing EPO.
Transkaryotic Therapies, Inc. (TKT) developed an alternative method of producing EPO using gene activation technology — a process that activated the endogenous EPO gene in human cells rather than introducing a foreign recombinant gene. Hoechst Marion Roussel (later Aventis) supported TKT’s development and planned to market the resulting EPO product. Amgen sued for infringement of multiple patents. A Massachusetts district court issued an exhaustive opinion after a bench trial, holding several of Amgen’s patents valid and infringed. TKT and Hoechst appealed, while Amgen cross-appealed certain rulings.
The Court’s Holding
The Federal Circuit affirmed the district court’s findings of validity and infringement for the core EPO product and pharmaceutical composition patents, vacated certain rulings, and remanded for further proceedings. Writing for the court, Judge Lourie upheld the district court’s conclusions that Amgen’s key patent claims satisfied the written description and enablement requirements of 35 U.S.C. § 112.
On written description, the court held that Amgen’s 1984 application adequately described the EPO protein by reference to its amino acid sequence and biological properties, as understood by skilled artisans at the time. The specification’s disclosure was sufficient to demonstrate that Amgen’s inventors were in possession of the claimed EPO proteins and EPO-producing cell lines at the time of filing. On enablement, the court found that Amgen had provided sufficient guidance to allow skilled practitioners to make and use the claimed EPO products without undue experimentation, given the level of skill in the art in 1984 and the detailed protocols disclosed in the specification.
The court also affirmed that TKT’s gene-activation process — which used human cells and targeted the endogenous EPO gene — still produced the same EPO protein covered by Amgen’s product claims. A product patent covers the product regardless of the process used to make it, so TKT’s different production approach did not avoid infringement of Amgen’s claims to the EPO protein and compositions themselves.
Key Takeaways
- Foundational recombinant protein patents can satisfy written description and enablement requirements even for broad genus claims when the specification adequately characterizes the protein and provides sufficient production guidance for the level of skill existing at the time of filing.
- Product claims (for proteins or pharmaceutical compositions) are infringed regardless of the process used to make the product — a competitor cannot avoid infringement of a product claim by using a different production method.
- Gene activation approaches — activating endogenous genes rather than introducing recombinant DNA — may still infringe product claims on the proteins produced, because the claims cover the product, not the production pathway.
- The court’s enablement analysis is time-sensitive: what constitutes undue experimentation is judged at the filing date, taking into account the state of the art and the skill of practitioners at that time.
- This decision was part of a long-running dispute that involved multiple appeals and established Amgen’s dominant position in the EPO market through its patent portfolio.
Why It Matters
Amgen v. Hoechst Marion Roussel is one of the most commercially significant Federal Circuit patent decisions of the early 2000s. Erythropoietin drugs generated billions of dollars annually for Amgen, and TKT’s gene activation approach represented a potentially disruptive competitive threat. The Federal Circuit’s affirmance of Amgen’s core EPO patents blocked TKT’s market entry and protected Amgen’s dominant position in a critical therapeutic area.
The decision also has lasting significance for biotechnology patent law: it confirmed that broad protein product claims — covering the protein itself regardless of how it is made — provide powerful protection for foundational biologics. This was a critical early establishment of the principle that would apply decades later in biosimilar litigation: that a patent covering a biological molecule protects it against any method of manufacture, not just the specific recombinant approach the original inventor used. For companies working in the emerging biologics space, the decision reinforced the extraordinary commercial and legal value of foundational protein patents.